How to Help Your Patients Find Nivestym in Stock: A Provider's Guide

When a patient can't fill their Nivestym (filgrastim-aafi) prescription, it's not just a logistical inconvenience — it's a patient safety issue. Neutropenia can be life-threatening, and delays in G-CSF therapy during or after myelosuppressive chemotherapy carry real clinical risk. This guide is designed to help your practice proactively manage Nivestym access issues before they become emergencies.

Why Patients Struggle to Find Nivestym

Most Nivestym access failures trace back to one of four root causes that your practice can help address:

1. Prescription sent to the wrong pharmacy type. Nivestym is a specialty biologic; many retail pharmacies don't stock it. Always send Nivestym prescriptions to specialty pharmacies.
2. Prior authorization not initiated at time of prescribing. PA processing takes time. Ideally, the PA should be submitted before the patient's first dose is needed.
3. Nivestym not on the patient's formulary. Some plans prefer Zarxio or Releuko. Knowing the plan's preferred G-CSF agent can reduce PA friction.
4. Localized inventory gaps. Even when PA is approved and the pharmacy is appropriate, local stock can be temporarily depleted around cycle dates.

Best Practice: Always Route to Specialty Pharmacy

Establish a standardized workflow for your practice: all G-CSF prescriptions — including Nivestym — should be routed to specialty pharmacies. Build relationships with your area's specialty pharmacy providers:

• CVS Specialty (1-800-237-2767)
• Walgreens Specialty Pharmacy (1-800-424-7090)
• Accredo Health Group (1-800-803-2523)
• Your institution's own hospital or cancer-center pharmacy, if available

PA Management: Proactive Steps That Save Time

Prior authorization for Nivestym is virtually universal across commercial payers and Medicare Advantage. Establish these workflows in your practice to minimize delays:

• Submit the PA at the time of chemo planning, not on the day the prescription is needed
• Include the ICD-10 code, chemotherapy regimen, cycle schedule, and ANC data (for SCN indications)
• Know the payer's preferred G-CSF agent before prescribing — it may be faster to prescribe the plan's preferred product if clinically equivalent
• For urgent situations, call the payer's PA department and request an expedited review (required by most plans within 72 hours for urgent requests)

When Nivestym Is Unavailable: A Practical Substitution Framework

When Nivestym is not available, use this decision framework to select a substitute:

1. Is this for PBPC mobilization (stem cell transplant prep)? Use Nivestym, Zarxio, or Neupogen (not Releuko).
2. Is this for H-ARS (radiation syndrome)? Use Neupogen, Zarxio, Releuko, or Nypozi (not Nivestym).
3. All other indications (chemo, AML, BMT, SCN)? Any of the filgrastim biosimilars can substitute — check payer formulary for preferred agent.

Always write a new prescription for the alternative product — biosimilars cannot be automatically dispensed in place of each other without a specific prescription under current law.

medfinder for Providers: Help Patients Find Local Stock

medfinder is a service that calls pharmacies near a patient's location to check which ones can fill their specific medication and dosage. For practices dealing with medication access questions regularly, directing patients to medfinder.com/providers can offload pharmacy-hunting calls from your staff. Results are texted directly to the patient.

Patient Cost Assistance: Resources to Share

Nivestym can be expensive for patients who are uninsured, underinsured, or face high specialty copays. The following resources are available:

• Pfizer Oncology Together Copay Program: Commercially insured patients may pay as little as $0 per treatment (up to $25,000 savings/calendar year). Providers can submit the copay claim form on the patient's behalf. Call 1-800-505-4426.
• Pfizer Patient Assistance Program: For uninsured or low-income patients. Eligibility based on income and insurance status. Call 1-800-675-8416.
• HealthWell Foundation, CancerCare, and PAN Foundation: Third-party foundations that may provide copay assistance for oncology medications.

Key Takeaways for Oncology Practices

• Always route Nivestym prescriptions to specialty pharmacies — not standard retail
• Submit prior authorization at the time of chemo planning, not day-of
• Have biosimilar alternatives pre-identified and know which payers prefer which agents
• Direct cost-burdened patients to Pfizer Oncology Together or medfinder.com/providers
• Nivestym is NOT approved for H-ARS — confirm indication before prescribing vs. alternative